BR0308202A - Tiazóis e oxazóis substituìdos que modulam a atividade de ppar - Google Patents

Tiazóis e oxazóis substituìdos que modulam a atividade de ppar

Info

Publication number
BR0308202A
BR0308202A BR0308202-4A BR0308202A BR0308202A BR 0308202 A BR0308202 A BR 0308202A BR 0308202 A BR0308202 A BR 0308202A BR 0308202 A BR0308202 A BR 0308202A
Authority
BR
Brazil
Prior art keywords
ppar activity
compounds
oxazoles
relates
substituted thiazoles
Prior art date
Application number
BR0308202-4A
Other languages
English (en)
Inventor
Xue-Min Cheng
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0308202A publication Critical patent/BR0308202A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

"TIAZóIS E OXAZóIS SUBSTITUìDOS QUE MODULAM A ATIVIDADE DE PPAR". A presente invenção refere-se a compostos de estruturas (1) e (2) que alteram a atividade de PPAR. A invenção refere-se também a sais farmaceuticamente aceitáveis dos compostos, composições farmaceuticamente aceitáveis compreendendo os compostos ou seus sais, e métodos de uso deles como agentes terapêuticos para tratamento ou prevenção de hiperlipidemia e hipercolesterolemia em um mamífero. A presente invenção referese também a um método de fabricação dos compostos descritos.
BR0308202-4A 2002-03-07 2003-03-03 Tiazóis e oxazóis substituìdos que modulam a atividade de ppar BR0308202A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36241102P 2002-03-07 2002-03-07
PCT/IB2003/000882 WO2003074051A1 (en) 2002-03-07 2003-03-03 Substituted thiazoles and oxazoles that modulate ppar activity

Publications (1)

Publication Number Publication Date
BR0308202A true BR0308202A (pt) 2004-12-21

Family

ID=27789158

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308202-4A BR0308202A (pt) 2002-03-07 2003-03-03 Tiazóis e oxazóis substituìdos que modulam a atividade de ppar

Country Status (15)

Country Link
US (3) US6867224B2 (pt)
EP (1) EP1480641A1 (pt)
JP (1) JP2005527509A (pt)
AR (1) AR038882A1 (pt)
AU (1) AU2003207914A1 (pt)
BR (1) BR0308202A (pt)
CA (1) CA2478164A1 (pt)
GT (1) GT200300054A (pt)
MX (1) MXPA04008627A (pt)
NI (1) NI200300039A (pt)
PA (1) PA8568601A1 (pt)
PE (1) PE20040190A1 (pt)
TW (1) TW200405812A (pt)
UY (1) UY27696A1 (pt)
WO (1) WO2003074051A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04003398A (es) * 2001-10-12 2004-11-22 Nippon Chemiphar Co Activador para el receptor o activado con el proliferador de peroxisoma.
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
AU2003303681A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Fused heterocyclic derivates as ppar modulators
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
RU2344135C2 (ru) * 2003-07-02 2009-01-20 Ф.Хоффманн-Ля Рош Аг Тиазолзамещенные индолилпроизводные и их применение в качестве модуляторов ppar
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
RU2367659C2 (ru) * 2003-11-05 2009-09-20 Ф.Хоффманн-Ля Рош Аг Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar)
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
KR100802864B1 (ko) * 2004-03-09 2008-02-12 에프. 호프만-라 로슈 아게 Ｐｐａｒ 활성화제로서 피라졸릴 인돌릴 유도체
CA2557789C (en) * 2004-03-09 2012-12-11 F.Hoffmann-La Roche Ag Pyrazolyl indolyl derivatives as ppar activators
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
US7405236B2 (en) * 2004-08-16 2008-07-29 Hoffman-La Roche Inc. Indole derivatives comprising an acetylene group
US20080096916A1 (en) * 2004-11-18 2008-04-24 Pfizer Inc. Drugs And Prodrugs Useful The Treatment Of Energy Balance In Ruminants
RU2416601C2 (ru) * 2005-02-25 2011-04-20 Оно Фармасьютикал Ко., Лтд. Соединение индола и его применение
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US8202686B2 (en) * 2007-03-22 2012-06-19 Advanced Liquid Logic, Inc. Enzyme assays for a droplet actuator
TW200927740A (en) * 2007-11-13 2009-07-01 Bial Portela & Ca Sa Process
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
EP2516669B1 (en) 2009-12-21 2016-10-12 Advanced Liquid Logic, Inc. Enzyme assays on a droplet actuator
AR080374A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida
CA2803159A1 (en) 2010-06-21 2011-12-29 Ono Pharmaceutical Co., Ltd. New crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutano
WO2013009927A2 (en) 2011-07-11 2013-01-17 Advanced Liquid Logic, Inc. Droplet actuators and techniques for droplet-based assays
JP6106179B2 (ja) * 2012-02-24 2017-03-29 武田薬品工業株式会社 芳香環化合物
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
CN109071435A (zh) * 2016-01-21 2018-12-21 耶路撒冷希伯来大学伊森姆研究发展公司 吲哚啉衍生物、包含它们的组合物及其用途
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DE60005973T2 (de) 1999-08-27 2004-05-13 Eli Lilly And Co., Indianapolis Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
US6639077B2 (en) * 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
AU2001268162A1 (en) 2000-06-02 2001-12-17 Cor Therapeutics, Inc. Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor
US6903227B2 (en) 2000-06-02 2005-06-07 Millennium Pharmaceuticals, Inc. Synthesis of 2-acyl substituted chromanes and intermediates thereof
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
HUP0300857A3 (en) 2000-08-23 2007-03-28 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
CA2448639A1 (en) 2001-05-29 2002-12-05 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives and medicinal use thereof
EA200400011A1 (ru) 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
ATE394376T1 (de) 2001-06-18 2008-05-15 Ono Pharmaceutical Co Tetrahydrochinolinderivatverbindung und die verbindung als wirkstoff enthaltendes arzneimittel
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US6833380B2 (en) * 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation

Also Published As

Publication number Publication date
NI200300039A (es) 2005-09-21
US6867224B2 (en) 2005-03-15
US20050107442A1 (en) 2005-05-19
PE20040190A1 (es) 2004-03-20
AU2003207914A1 (en) 2003-09-16
JP2005527509A (ja) 2005-09-15
CA2478164A1 (en) 2003-09-12
TW200405812A (en) 2004-04-16
AR038882A1 (es) 2005-02-02
GT200300054A (es) 2003-10-10
US20050113422A1 (en) 2005-05-26
WO2003074051A1 (en) 2003-09-12
UY27696A1 (es) 2003-10-31
EP1480641A1 (en) 2004-12-01
US7109222B2 (en) 2006-09-19
PA8568601A1 (es) 2003-11-12
MXPA04008627A (es) 2004-12-06
US20030207915A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
BR0308202A (pt) Tiazóis e oxazóis substituìdos que modulam a atividade de ppar
BR0308221A (pt) Derivados de tiazol e oxazol que modulam a atividade de ppar
BR0308277A (pt) Derivados tiazol e oxazol que modulam a atividade de ppar
BRPI0409486A (pt) compostos que modulam atividade de ppar e métodos para a sua preparação
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BR0311375A (pt) Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
DK0735868T3 (da) Anvendelse af ikke-steroide cyclooxygenaseinhibitorer til fremstilling af et medikament til behandling af forhøjet intrakul
BR9711095A (pt) Composto de ciclopentano substituìdo, composição e método para inibir neuraminidase de vìrus influenza e método para tratar infecção de vìrus influenza
BR0015436A (pt) Sais de hidroxieicosatetraenoato, composições e métodos de uso no tratamento de distúrbios dos olhos secos
DE59802356D1 (de) Lagerstabile ophthalmische zusammensetzungen, umfassend diclofenac und ofloxacin
DK1317262T3 (da) Topisk påført koncentreret sammensætning til hovbehandling
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BR0314843A (pt) Novo composto
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
BRPI0410654A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR9707674A (pt) Uso de inibidores de anidrase carbÈnico para tratamento de edema macular.
BR0010084A (pt) Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
BR0318659A (pt) derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores
BR0211358A (pt) Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.